Imprime significantly enhanced the activity of an anti-MUC1 tumor-targeting antibody in a syngeneic T cell lymphoma model engineered to express the cell surface protein MUC1. The gene discussed is MUC1; the disease is T-cell non-Hodgkin lymphoma.